1008 related articles for article (PubMed ID: 28667006)
1. Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma.
Jusakul A; Cutcutache I; Yong CH; Lim JQ; Huang MN; Padmanabhan N; Nellore V; Kongpetch S; Ng AWT; Ng LM; Choo SP; Myint SS; Thanan R; Nagarajan S; Lim WK; Ng CCY; Boot A; Liu M; Ong CK; Rajasegaran V; Lie S; Lim AST; Lim TH; Tan J; Loh JL; McPherson JR; Khuntikeo N; Bhudhisawasdi V; Yongvanit P; Wongkham S; Totoki Y; Nakamura H; Arai Y; Yamasaki S; Chow PK; Chung AYF; Ooi LLPJ; Lim KH; Dima S; Duda DG; Popescu I; Broet P; Hsieh SY; Yu MC; Scarpa A; Lai J; Luo DX; Carvalho AL; Vettore AL; Rhee H; Park YN; Alexandrov LB; Gordân R; Rozen SG; Shibata T; Pairojkul C; Teh BT; Tan P
Cancer Discov; 2017 Oct; 7(10):1116-1135. PubMed ID: 28667006
[TBL] [Abstract][Full Text] [Related]
2. Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma.
Kongpetch S; Jusakul A; Lim JQ; Ng CCY; Chan JY; Rajasegaran V; Lim TH; Lim KH; Choo SP; Dima S; Popescu I; Duda DG; Kukongviriyapan V; Khuntikeo N; Pairojkul C; Rozen SG; Tan P; Teh BT
JCO Glob Oncol; 2020 Apr; 6():628-638. PubMed ID: 32315234
[TBL] [Abstract][Full Text] [Related]
3. Genomic and transcriptional alterations of cholangiocarcinoma.
Ito T; Sakurai-Yageta M; Goto A; Pairojkul C; Yongvanit P; Murakami Y
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):380-7. PubMed ID: 24532422
[TBL] [Abstract][Full Text] [Related]
4. Genetics of Opisthorchis viverrini-related cholangiocarcinoma.
Jusakul A; Kongpetch S; Teh BT
Curr Opin Gastroenterol; 2015 May; 31(3):258-63. PubMed ID: 25693006
[TBL] [Abstract][Full Text] [Related]
5. Whole-exome mutational and transcriptional landscapes of combined hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma reveal molecular diversity.
Liu ZH; Lian BF; Dong QZ; Sun H; Wei JW; Sheng YY; Li W; Li YX; Xie L; Liu L; Qin LX
Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2360-2368. PubMed ID: 29408647
[TBL] [Abstract][Full Text] [Related]
6. The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.
Chong DQ; Zhu AX
Oncotarget; 2016 Jul; 7(29):46750-46767. PubMed ID: 27102149
[TBL] [Abstract][Full Text] [Related]
7. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.
Moeini A; Sia D; Zhang Z; Camprecios G; Stueck A; Dong H; Montal R; Torrens L; Martinez-Quetglas I; Fiel MI; Hao K; Villanueva A; Thung SN; Schwartz ME; Llovet JM
J Hepatol; 2017 May; 66(5):952-961. PubMed ID: 28126467
[TBL] [Abstract][Full Text] [Related]
8. CpG-island methylation study of liver fluke-related cholangiocarcinoma.
Sriraksa R; Zeller C; El-Bahrawy MA; Dai W; Daduang J; Jearanaikoon P; Chau-In S; Brown R; Limpaiboon T
Br J Cancer; 2011 Apr; 104(8):1313-8. PubMed ID: 21448164
[TBL] [Abstract][Full Text] [Related]
9. Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles.
Farshidfar F; Zheng S; Gingras MC; Newton Y; Shih J; Robertson AG; Hinoue T; Hoadley KA; Gibb EA; Roszik J; Covington KR; Wu CC; Shinbrot E; Stransky N; Hegde A; Yang JD; Reznik E; Sadeghi S; Pedamallu CS; Ojesina AI; Hess JM; Auman JT; Rhie SK; Bowlby R; Borad MJ; ; Zhu AX; Stuart JM; Sander C; Akbani R; Cherniack AD; Deshpande V; Mounajjed T; Foo WC; Torbenson MS; Kleiner DE; Laird PW; Wheeler DA; McRee AJ; Bathe OF; Andersen JB; Bardeesy N; Roberts LR; Kwong LN
Cell Rep; 2017 Mar; 18(11):2780-2794. PubMed ID: 28297679
[TBL] [Abstract][Full Text] [Related]
10. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers.
Chan-On W; Nairismägi ML; Ong CK; Lim WK; Dima S; Pairojkul C; Lim KH; McPherson JR; Cutcutache I; Heng HL; Ooi L; Chung A; Chow P; Cheow PC; Lee SY; Choo SP; Tan IB; Duda D; Nastase A; Myint SS; Wong BH; Gan A; Rajasegaran V; Ng CC; Nagarajan S; Jusakul A; Zhang S; Vohra P; Yu W; Huang D; Sithithaworn P; Yongvanit P; Wongkham S; Khuntikeo N; Bhudhisawasdi V; Popescu I; Rozen SG; Tan P; Teh BT
Nat Genet; 2013 Dec; 45(12):1474-8. PubMed ID: 24185513
[TBL] [Abstract][Full Text] [Related]
11. Genome wide DNA copy number analysis in cholangiocarcinoma using high resolution molecular inversion probe single nucleotide polymorphism assay.
Arnold A; Bahra M; Lenze D; Bradtmöller M; Guse K; Gehlhaar C; Bläker H; Heppner FL; Koch A
Exp Mol Pathol; 2015 Oct; 99(2):344-53. PubMed ID: 26260902
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention.
Lowery MA; Ptashkin R; Jordan E; Berger MF; Zehir A; Capanu M; Kemeny NE; O'Reilly EM; El-Dika I; Jarnagin WR; Harding JJ; D'Angelica MI; Cercek A; Hechtman JF; Solit DB; Schultz N; Hyman DM; Klimstra DS; Saltz LB; Abou-Alfa GK
Clin Cancer Res; 2018 Sep; 24(17):4154-4161. PubMed ID: 29848569
[No Abstract] [Full Text] [Related]
13. Global alterations of DNA methylation in cholangiocarcinoma target the Wnt signaling pathway.
Goeppert B; Konermann C; Schmidt CR; Bogatyrova O; Geiselhart L; Ernst C; Gu L; Becker N; Zucknick M; Mehrabi A; Hafezi M; Klauschen F; Stenzinger A; Warth A; Breuhahn K; Renner M; Weichert W; Schirmacher P; Plass C; Weichenhan D
Hepatology; 2014 Feb; 59(2):544-54. PubMed ID: 24002901
[TBL] [Abstract][Full Text] [Related]
14. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.
Churi CR; Shroff R; Wang Y; Rashid A; Kang HC; Weatherly J; Zuo M; Zinner R; Hong D; Meric-Bernstam F; Janku F; Crane CH; Mishra L; Vauthey JN; Wolff RA; Mills G; Javle M
PLoS One; 2014; 9(12):e115383. PubMed ID: 25536104
[TBL] [Abstract][Full Text] [Related]
15. Gatekeeper Mutations and Intratumoral Heterogeneity in
Smyth EC; Babina IS; Turner NC
Cancer Discov; 2017 Mar; 7(3):248-249. PubMed ID: 28264865
[TBL] [Abstract][Full Text] [Related]
16. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma.
Montal R; Sia D; Montironi C; Leow WQ; Esteban-Fabró R; Pinyol R; Torres-Martin M; Bassaganyas L; Moeini A; Peix J; Cabellos L; Maeda M; Villacorta-Martin C; Tabrizian P; Rodriguez-Carunchio L; Castellano G; Sempoux C; Minguez B; Pawlik TM; Labgaa I; Roberts LR; Sole M; Fiel MI; Thung S; Fuster J; Roayaie S; Villanueva A; Schwartz M; Llovet JM
J Hepatol; 2020 Aug; 73(2):315-327. PubMed ID: 32173382
[TBL] [Abstract][Full Text] [Related]
17. Molecular classification of cholangiocarcinoma.
Louis C; Papoutsoglou P; Coulouarn C
Curr Opin Gastroenterol; 2020 Mar; 36(2):57-62. PubMed ID: 31895230
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of p53 and Its Target Gene Expression as Potential Biomarkers of Cholangiocarcinoma in Thai Patients.
Puetkasichonpasutha J; Namwat N; Sa-Ngiamwibool P; Titapun A; Suthiphongchai T
Asian Pac J Cancer Prev; 2020 Mar; 21(3):791-798. PubMed ID: 32212809
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of a CpG island methylator phenotype-related prognostic signature for cholangiocarcinoma.
Liang J; Liu T; Liao J; Zhang L; Zhou M; Xu W; He Y; Cai G; Jin G; Song J; Li G; Liang H; Ding Z; Zhang B
J Cell Physiol; 2021 Apr; 236(4):3143-3156. PubMed ID: 32996133
[TBL] [Abstract][Full Text] [Related]
20. Driver mutations of intrahepatic cholangiocarcinoma shape clinically relevant genomic clusters with distinct molecular features and therapeutic vulnerabilities.
Wang XY; Zhu WW; Wang Z; Huang JB; Wang SH; Bai FM; Li TE; Zhu Y; Zhao J; Yang X; Lu L; Zhang JB; Jia HL; Dong QZ; Chen JH; Andersen JB; Ye D; Qin LX
Theranostics; 2022; 12(1):260-276. PubMed ID: 34987644
[No Abstract] [Full Text] [Related]
[Next] [New Search]
